GLYCOPEPTIDE ANTIBIOTICS MARKET ANALYSIS

Glycopeptide Antibiotics Market, by Drug (Vancocin, Orbactiv, Dalvance, Kimyrsa, and Others), by Disease Indication (Clostridium difficile-associated Diarrhea, Endocarditis, Skin Structure Infections, and Others), by Distribution channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jan 2023
Code : CMI5455
Pages :154
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Global Glycopeptide Antibiotics Market - Drivers

The increasing cases of cancer and infectious diseases such as enterococcal infections, Hepatitis and others is expected to drive the market growth during the forecast period. For instance, according to data published in September 2022 by the Centers for Disease Control and Prevention (CDC), the number of tuberculosis cases in the year 2019 in the U.S. was 8,916.

Increasing product approvals for the treatment of infectious diseases are expected to drive the market growth during the forecast period. For instance, in July 2021, AbbVie Inc., a U.S. biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved DALVANCE for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Global Glycopeptide Antibiotics Market: Restraint

The major factors that hinder growth of the global glycopeptide antibiotics market include increase in glycopeptide antibiotic resistance cases. For instance, according to Antibiotic Resistance Threats Report in the United States, 2019, Enterococcus which is Vancomycin (glycopeptide antibiotic) resistant bacteria caused 5,400 deaths in U.S. in 2019.